Interferon-g (IFNg) is an important immunoregulatory cytokine that can also decrease intestinal epithelial barrier function. Little is known about the intracellular signalling events immediately subsequent to IFNg/IFNg receptor interaction that mediate increases in epithelial permeability; data that could be used to ablate this effect of IFNg while leaving its immunostimulatory effects intact. This study assessed the potential involvement of Src family kinases in IFNg-induced increases in epithelial permeability using confluent filter-grown monolayers of the human colon-derived T84 epithelial cell line. Inhibition of Src kinase with the pharmacologic PP1 and use of Fyn kinase-specific siRNA significantly reduced IFNg-induced increases in epithelial permeability as gauged by translocation of noninvasive E. coli (HB101 strain) and flux of horseradish peroxidase (HRP) across monolayers of T84 cells. However, the drop in transepithelial resistance elicited by IFNg was not affected by either treatment. Immunoblotting revealed that IFNg activated the transcription factor STAT5 in T84 cells, and immunoprecipitation studies identified an IFNg-inducible interaction between STAT5b and the PI3K regulatory subunit p85a through formation of a complex requiring the adaptor molecule Gab2. siRNA targeting STAT5b and Gab2 reduced IFNg-induced increases in epithelial permeability and phosphorylation of PI3K(p85a). PP1 and Fyn siRNA reduced IFNg-induced PI3K activity (indicated by decreased phospho-Akt) and the formation of the STAT5b/PI3K(p85a) complex. Collectively, the results suggest the formation of a Fyn-dependent STAT5b/Gab2/PI3K complex that links IFNg to PI3K signalling and the regulation of macromolecular permeability in a model enteric epithelium.
The intestinal epithelium is critical in the maintenance of health. It is responsible for nutrient and water absorption, it acts as an innate immune barrier to microbes entering the mucosa and it is increasingly appreciated as a regulator of mucosal immunity. 1 Controlled and transient increases in epithelial permeability are homeostatic events, yet aberrant and prolonged loss of barrier function could mediate entry of excessive amounts of antigen and microbes into the mucosa to elicit inflammatory disease, as has been proposed for inflammatory bowel disease (IBD). 2, 3 Moreover, should bacteria move from the lumen of the gut into the bloodstream, the outcome can be sepsis and multiorgan failure.
Interferon-g (IFNg) is an immunoregulatory cytokine whose functions include increasing MHC I and II expression, activation of macrophages and regulation of T helper cell differentiation. Levels of IFNg are often elevated, locally and systemically, following microbial infection and in chronic inflammatory diseases including IBD. 4 In addition to its pivotal role in immune regulation, numerous in vitro, and a lesser number of in vivo, studies reveal that IFNg decreases enteric epithelial barrier function. [5] [6] [7] IFNg-induced disruption of epithelial barrier function is accompanied by reduced expression of the tight junction (TJ) proteins, zonula occludens (ZO)-1 and occludin, 6, 7 and this would allow increased permeation of material between adjacent cells via the paracellular pathway. 8 We, and others, have shown that IFNg can promote the transcytosis of bacteria across epithelial monolayers. 9, 10 Consequently, the elucidation of IFNgmediated intracellular signalling pathways can be pursued with the ambition of identifying epithelial target molecules, the inhibition of which would ablate IFNg-induced increases in gut permeability while not interfering with its ability to activate immune cells to eliminate bacteria that gain access to the mucosa.
Canonical IFNg signalling involves the phosphorylation, dimerization and nuclear translocation of signal transducer and activator of transcription (STAT)-1. 11 Pharmacological inhibition of STAT1 tyrosine phosphorylation (ie, activation) failed to ameliorate IFNg-induced reduction in transepithelial electrical resistance (TER, a marker of paracellular permeability), and subsequently a requirement for activation of PI3K during IFNg-induced increases in epithelial permeability across monolayers of human colon-derived epithelial cell lines was shown. 10, 12 However, there is no indication that PI3K can bind the IFNg receptor, 13 and hence intermediate structural or kinase molecules are needed to convert IFNg/IFNg receptor (IFNgR) interaction into PI3K activation.
Src kinases are a family of nonreceptor-associated tyrosine kinases that regulate several cell processes including cell growth and migration.
14 Src has been implicated in STAT5 activation in response to hematopoietic growth factors and malignancy, 15 and may lie upstream of PI3K activation, serving as a component of growth factor signalling. 16, 17 Activation of STAT5 in T-cell lines by IFNg has been shown but similar findings in epithelia have not been reported, whereas Src activity has been implicated in IFNg regulation of Cl À secretion in the T84 epithelial cell line. [18] [19] [20] Thus, we hypothesized that a Src kinase and/or STAT5 were intermediate molecules between the IFNgR and PI3K in the regulation of epithelial barrier function.
The findings presented in this study suggest a novel signalling pathway whereby IFNg stimulates the activity of the Src kinase Fyn, leading to the formation of a complex containing STAT5b, Gab2 and the p85a regulatory subunit of PI3K. The complex assembly results in PI3K activation and a consequent increase in the macromolecular permeability characteristics of monolayers of the human colon-derived T84 epithelial cell line.
MATERIALS AND METHODS Reagents
Reagents, including cell culture supplements and pharmacological inhibitors, were purchased from Sigma-Aldrich (Oakville, ON, Canada) unless otherwise indicated. Src inhibitor PP1 was purchased from Biomol (Enzo Life Sciences, Plymouth Meeting, PA, USA) and LY294002 and AG490 were purchased from Calbiochem (EMD Chemicals, Gibbstown, NJ, USA). Recombinant human IFNg was purchased from Ebioscience (San Diego, CA, USA). Rabbit anti-STAT5a/b, anti-phosphotyrosine (694/699) STAT5a/b, anti-Akt, anti-phosphoserine (473) Akt, anti-STAT1a/b, antiphosphotyrosine (701) STAT1, anti-phosphotyrosine (452) Gab2, anti-phosphotyrosine (416) Src family and mouse anti-c-Src antibodies were purchased from Cell Signaling Technologies (NEB, Oakville, ON, Canada). Mouse antiSTAT5b was from Invitrogen (Burlington, ON, Canada) and mouse anti-Fyn kinase, rabbit anti-interferon response factor-1 (IRF-1) and goat anti-actin antibodies were purchased from Santa Cruz Biotech (Santa Cruz, CA, USA). Mouse anti-PI3K p85a, rabbit anti-Gab2 and mouse antiphosphotyrosine (4G10) were purchased from Millipore (Billerica, MA, USA). Mouse anti-IFNgR2 was purchased from Abcam (Cambridge, MA, USA). Control mouse IgG and horseradish peroxidase (HRP)-conjugated secondary antibodies were purchased from Santa Cruz. Phosphoinositide 3,4,5, triphosphate (PIP 3 ) Mass ELISA kits were purchased from Echelon Biosciences (Salt Lake City, UT, USA). Nonpathogenic, noninvasive E. coli strain HB101 was a kind gift from Dr PM Sherman (Hospital for Sick Children, University of Toronto, Toronto, ON, Canada).
Cell Culture
The immortalized human colon-derived T84 epithelial cell line (ATCC, Manassas, VA, USA) was cultured at 37 1C/5% CO 2 in 1:1 Dulbecco's modified Eagle's medium/Ham's F-12 medium supplemented with 2% (v/v) penicillin-streptomycin, 1.5% HEPES, 5% NaHC0 3 , 1% L-glutamine, 1% sodium pyruvate (all from Invitrogen) and 10% fetal bovine serum (PAA Laboratories, VWR International, Edmonton, AB, Canada). For assay of epithelial barrier function, 1 Â 10 6 cells (1 ml volume) were seeded onto 12 mm 2 semi-permeable filter supports (3.0 mm pore size; Greiner Biosciences (VWR)) and cultured until electrically confluent (see below). For immunoprecipitation (IP) and immunoblotting experiments, 1 Â 10 6 T84 cells/well were seeded in 12-well culture dishes and cultured until confluent as assessed by phasecontrast microscopy. For PIP 3 synthesis assays, 5 Â 10 6 cells were seeded onto 150 mm culture dishes and grown to confluence. In other experiments, cells of the human colonderived Caco2 cell line were cultured and treated in a manner identical to that used for T84 cells.
In some signalling experiments, THP-1 cells (human monocytic cell line; ATCC) were differentiated by treatment with 20 nM phorbol-12-myristyl-13-acetate (PMA) for 48 h, and cells developed a stellate morphology typical of macrophages (see Figure3b, inset). Cells were subsequently stimulated with 10 ng/ml IFNg over the indicated times.
Transient Transfection of T84 Cells with Small
Interfering RNA (siRNA) siRNAs targeting STAT1, STAT5b, Gab2, Fyn and c-Src (and appropriate scrambled oligomer controls) were created using the Stealth siRNA oligomer design platform (Invitrogen); target oligomer sequences used in this study are shown in Table 1 . A total of 20 pmol of specific or scrambled control siRNA in Lipofectamine 2000/Opti-MEM (500 mg/ml; Invitrogen) was added to suspension cultures of T84 cells (1 Â 10 6 /ml) in antibiotic-free FBS-containing culture medium. The cells were then either seeded onto filter supports for permeability experiments or 12-well culture dishes for signalling experiments. Following an overnight incubation, adherent cells were washed and transferred to antibioticcontaining culture medium until reaching confluence and assays were conducted as described below.
Epithelial Barrier Function
For assessment of epithelial barrier function, filter-grown T84 or Caco2 cell monolayers were treated with IFNg (10 ng/ml)±pharmacological inhibitors (unless using siRNA transfected cells) added to the basal chamber of the culture well. Treatments were conducted in triplicate.
Transepithelial electrical resistance TER across filter-grown T84 cells was assessed using a voltmeter and companion electrodes (Millipore). Monolayers in this study were considered electrically confluent when TER values were Z1000 Ohms Á cm 2 , which typically occurred after 4-7 days of culture. 21 Individual monolayer TER was measured at the start of each experiment (baseline value) and 24 and 48 h thereafter.
HRP fluxes
Immediately after the addition of IFNg ± pharmacological inhibitors (times and doses denoted on figures) to T84 cell monolayers, HRP (20 ng type VI) was added to the apical chamber (1 ml vol.) of the well, and 48 h later, three 10 ml samples of culture medium were collected from the basolateral chamber, diluted (1:10) in 0.5% HTAB buffer and HRP activity determined by spectrophotometric measurement (OD 450 nm) of 3,3 0 ,5,5 0 -tetramethylbenzidine (TMB) oxidation after the reaction was terminated with 2 N H 2 SO 4 . The amount of HRP was quantified against a standard concentration curve.
Bacterial translocation
Confluent T84 cell monolayers were transferred to antibioticfree culture medium, noninvasive E. coli (strain HB101, 10 5 CFU) were added to the apical surface of the epithelium, and IFNg simultaneously added to the basolateral chamber (±inhibitors as indicated). After 24 h, 100 ml aliquots of basolateral media were collected, serial log dilutions made in PBS and plated on antibiotic-free LB-Agar plates. Cultures were incubated overnight at 37 1C/5% CO 2 and resultant bacterial colonies were counted. Pharmacological inhibitors were tested for bacteriocidal or bacteriostatic activity by conducting E. coli growth assays in the presence or absence of experimental concentrations of the Src inhibitor, PP1 or the PI3K inhibitor, LY294002.
IP and Immunoblotting
Whole cell lysates were prepared by washing with ice-cold PBS, followed by scraping cells into ice-cold Triton X-100 buffer (25 mM Tris-HCl (pH 8), 125 mM NaCl, 5 mM EDTA, 1% (v/v) Triton X-100) supplemented with protease and phosphatase inhibitors (Completes protease inhibitor cocktail (Roche/Mannheim), 1 mM sodium orthovanadate, 1 mM sodium fluoride). Lysates were incubated with gentle agitation at 4 1C for 30 min, centrifuged at 10 000 g and supernatants were collected and stored at À80 1C. Protein concentrations were determined by Bradford assay (Bio-Rad, Hercules, CA, USA). Crude membrane extracts were prepared by lysing cells in Triton X-100 buffer as above, followed by dissolution of the pelleted fraction in 1% SDS/PBS at 65 1C for 15 min followed by centrifugation.
For immunoblotting, 20 mg of lysates was added to Laemmli buffer, boiled and resolved on 8% SDS-PAGE. With 1% SDS/PBS (membrane) lysates estimated equivalent quantities (adjusted to Triton X-100 protein lysate concentrations) were used. Separated proteins were blotted to Immobilon nitrocellulose membranes (Millipore), and blots were blocked at room temperature for 1 h in 5% nonfat milk/ wash buffer (0.1% Tween-20/Tris-buffered saline (TBS/T)). Primary antibodies (for proteins as indicated in Results) were incubated in 1% bovine serum albumin/TBS/T (for phosphoprotein analysis) or 5% non-fat milk/TBS/T (total proteins) overnight at 4 1C with gentle rocking. Blots were 
Sequence selection and accession numbers for gene products selected for siRNA targeting. Shown are the sequences used for targeting of the indicated gene products; multiple siRNAs were designed for each protein target but sequences shown were used for the presented studies. Control oligomeric sequences are listed below each target. RNA oligomers were designed and synthesized using Stealth RNAi (Invitrogen).
IFNc and epithelial permeability D Smyth et al washed three times in TBS/T and species-appropriate, HRPconjugated secondary antibodies were applied with gentle rocking for 1 h at room temperature. Blots were washed, subjected to chemiluminescence (Western Lightnings PLUS, PerkinElmer, Waltham, MA, USA) and subsequently exposed to Kodak XB-1 film (Eastman Kodak, Rochester, NY, USA). For IP, 300 mg of protein from total cell lysates was incubated with gentle rocking overnight at 4 1C with 2 mg/ml of indicated monoclonal antibody for a specific signalling or structural protein or an irrelevant IgG as a control for the IP process. Subsequently, immune complexes were adsorbed with EZ-view protein A-agarose beads (Sigma; 30 ml per sample) by 1.5 h of gentle rocking at 4 1C. Complexes were repeatedly washed with lysis buffer and once with PBS or TBS, and proteins were eluted in Laemmli buffer, boiled and resolved on SDS-PAGE for immunoblotting.
Where indicated, densitometric analyses were conducted on blots using Image J open-access software (NIH, Bethesda, MD, USA). ) were seeded onto 15 cm culture dishes and cultured to B80% confluence and subsequently treated with IFNg (20 ng/ml) for the indicated times or with human epidermal growth factor (EGF; 20 ng/ml for 30 min; a positive control for PI3K activation). Extraction of phosphoinositide lipids and a competitive ELISA for measurement of PIP 3 was carried out as specified by the manufacturer's protocols.
Plastic-grown T84 epithelial cell monolayers were treated with IFNg±LY294002 (pan-PI3K inhibitor), and the amount of IP-10 liberated into the culture medium 24 h (or 48 h) later was determined using Luminex technology.
Statistical analysis
Graphical data are presented as mean±s.d., with n denoting the number of T84 cell preparations from a defined number of experiments. Where appropriate, data were assessed using Student's t-test or one-way analysis of variance (ANOVA) followed by post hoc pair-wise statistical comparisons with Tukey's or Dunnett's test. A statistical significance was deemed achieved if Po0.05.
RESULTS

Pharmacological Inhibition of Src Kinases Reduces IFNc-Induced Increases in Epithelial Permeability
A role for Src kinase in IFNg regulation of Cl À secretion by T84 cells has been shown; 18 therefore, it was of interest to determine if IFNg-mediated increases in epithelial permeability were influenced by Src kinase activity. As shown in Figure 1a and b, the increased passage of HRP and E. coli (strain HB101) across IFNg-treated (10 ng/ml) T84 cell monolayers was abolished by co-treatment with the Src kinase inhibitor PP1 (125 nM) and the PI3K inhibitor, LY294002 (20 mM) (neither drug had bacteriostatic properties). Using transepithelial flux of HRP as a marker of epithelial barrier function, dose-and time-response studies revealed that 30 nM PP1 blocked the IFNg-induced increased transepithelial flux of HRP and the drug was equally effective if added 30 min before or 90 min after IFNg exposure (Figure 1c and d) . IFNg-induced increased HRP transcytosis across monolayers of Caco2 cells was also significantly reduced by PP1 (Figure 1c and d) . In contrast, the drop in TER elicited by IFNg was not affected by Src kinase inhibition (Figure 1e ), whereas consistent with earlier studies, 10, 12 inhibition of PI3K activity did reduce, in part, the drop in TER.
To examine Src activation, we assessed IFNg-stimulated Src phosphorylation at the Y416 residue (an auto-phosphorylation site) 2 h post-cytokine application (Figure 1f) . Phosphorylation of two immunoreactive products migrating at B60 kDa in size was observed, with marked increase of phosphorylation apparent for the smaller Src form. Phosphorylation of the smaller form was reduced in cells treated with the Src inhibitor, PP1, whereas the larger molecule appeared unaltered.
Downregulation of Fyn Kinase Inhibits IFNc-Stimulated Increases in Epithelial Permeability
Although PP1 is a general Src kinase inhibitor, at 30 nM only the activity of Src family kinase members Lck, Hck or Fyn are effectively blocked. 22 As Lck and Hck expression is largely restricted to immune cell types, 23 we assessed whether Fyn participated during IFNg signalling responses in T84 cells. Co-immunoprecipitation studies using Fyn monoclonal antibody showed an increased association of Fyn with the IFNgR2 subunit of the IFNg receptor within 15 min of IFNg application to T84 cells cultures (Figure 2a ). Subsequently, siRNA targeting Fyn was used to assess a role for this Src kinase in IFNg regulation of T84 epithelial monolayer permeability. Anti-Fyn siRNA reduced expression of Fyn protein by T84 cells within 96 h of transfection, the time determined to be required for T84 monolayers to reach electrical confluence (Figure 2b ). Consistent with studies using PP1, specific Fyn knockdown inhibited IFNg-stimulated translocation of HRP and E. coli fluxes across T84 monolayers (Figure 2c IFNc Induces STAT1 and STAT5 Phosphorylation in T84 Cells Independent of Src Activity IFNg treatment resulted in STAT1 and STAT5 phosphorylation in both T84 and Caco2 cells (Figure 3a) . Analysis of T84 cells revealed that whereas phosphorylation of STAT1 was markedly increased within 30 min of IFNg exposure, STAT5 phosphorylation was somewhat slower and less robust, peaking at 2 to 3 h post-IFNg. The protracted expression of phosphorylated STAT1 and STAT5 in IFNg-treated T84 cells (and STAT5 in Caco2 cells) was not observed in THP-1 cells differentiated to a macrophage phenotype, where phosphorylation of either molecule was maximal after 15 min and markedly diminished 2 h post-IFNg treatment (Figure 3b) . The increase in STAT1 and STAT5 phosphorylation observed in T84 epithelia at 2 and 6 h after IFNg treatment was unaffected by Src kinase inhibition with PP1 or Fyn siRNA (Figure 3c and d) . 
STAT5b and Gab2 Are Required for IFNc-Stimulated Increases in Epithelial Permeability and to Interact with PI3K in an IFNc-Inducible Complex
We subsequently focused on STAT5b as a mediator of IFNgdriven increases of epithelial cell permeability, as it is known to interact with the PI3K pathway in hematopoietic cell lines following growth factor stimulation. Notably, STAT5-dependent, PI3K-activating complexes can be induced via coupling to the signalling adaptor Gab2. 24, 25 STAT5b-and Gab2-specific, but not control, siRNAs significantly reduced the IFNg-induced increase in E. coli translocation and transepithelial fluxes of HRP across T84 cell monolayers (Figure 5a and b) . Both siRNAs reduced expression of the respective proteins at 96 h after transfection (Figure 5c ). Consistent with experiments utilizing the Src inhibitor PP1 or Fyn siRNA, the drop in T84 monolayer TER evoked by IFNg was affected by knockdown of neither STAT5b nor Gab2 (data not shown). Furthermore, IFNg activation of Fyn (ie, phosphorylated on Tyr 416) in the cell membrane was markedly reduced by siRNA against both Fyn and STAT5b (Figure 5d ).
IFNg induces PI3K activity as measured by PIP 3 formation (Figure 6a ) and phosphorylation of the PI3K-regulated serine/ threonine kinase Akt (Figure 6b ), which was inhibited by LY2940. Immune complexes precipitated with anti-STAT5b show increased association of Gab2 and PI3K p85a 6 h postIFNg stimulation (Figure 6c ). Reciprocal blots following IP with anti-PI3K p85a antibodies revealed increased association with STAT5b and Gab2 in response to IFNg (data not shown).
Fyn Kinase Is Required for Formation of STAT5b/ PI3K(P85a) Complexes Stimulated by IFNc in T84 Cells
PI3K activation in response to select stimuli can be dependent upon the activity of Src kinases including Fyn; 26 thus, we assessed whether Fyn was required for IFNg-stimulation of PI3K activity in T84 cells. Fyn knockdown reduced the phosphorylation of Gab2 (Tyr452, contained within a putative YVPM p85a binding site) evoked by IFNg stimulation (Figure 7a) . Akt phosphorylation observed 6 h after IFNg treatment was also reduced by Fyn siRNA treatment; both findings were corroborated by treatment with PP1, given 90 min after IFNg treatment (Figure 7b ). Subsequent co-immunoprecipitation studies revealed that association of STAT5b and Gab2 with p85a at 6 h post-IFNg stimulation was reduced by Fyn-specific siRNA (Figure 7c) , findings that were reproduced in PP1-treated T84 monolayers (Figure 7d ).
Neither PI3K Inhibition Nor Fyn Knockdown Interfere with STAT1 Signalling in T84 Epithelia
Initial studies showed that Src kinase inhibition with PP1 or Fyn siRNA did not appreciably affect IFNg-induced STAT1 phosphorylation in T84 cells (Figure 4b and c) . Therefore, we assessed the effects of Src inhibition upon expression of a STAT1-dependent gene product, IRF-1. Increased IRF-1 protein expression was observed by 6 h post-IFNg stimulation and was unaffected by treatment with PP1 (Figure 8a) or (Figure 8b) . Furthermore, the induction and release of the IFNg STAT1-dependent cytokine, IP-10, was not inhibited in T84 cells co-treated with LY294002 (control ¼ 0.06±0.02, IFNg treated ¼ 13.7±0.5 and IFNg þ LY294002 treated ¼ 11.9±1.6 ng/ml; n ¼ 3).
DISCUSSION
Analyses of human enteric epithelial cell lines and murine models of gut dysfunction reveal that IFNg can significantly increase epithelial permeability. 27, 28 As the intestinal epithelium is the primary interface between the body and the external environment, IFNg-induced decreases in epithelial barrier function would allow potentially dangerous stimuli (eg, low-grade pathogens, commensal bacteria, unprocessed antigen) into the mucosa that could precipitate or exaggerate existing inflammation. Consequently, knowledge of the epithelial intracellular signalling events engaged by IFNg that reduce barrier function could allow for the formulation of therapies to limit the increases in gut permeability, with the advantage of leaving the impact of IFNg on immune cells intact.
The ability of IFNg to increase epithelial permeability was demonstrated B20 years ago. 27 Since then, substantial data have accumulated showing that IFNg increases epithelial paracellular permeability (evidenced by increased flux of small inert molecules and loss or internalization of TJ proteins), that a considerable time lag (24-48 h) exists between IFNg exposure and reduced epithelial integrity and that apoptosis is not a major cause of the increased epithelial permeability. 6, 29 However, there remains a lack of information on the intracellular signalling events proximal to the IFNgR that induce IFNg-mediated increases of epithelial permeability.
JAK/STAT1 signalling is recognized as an important component of IFNg-stimulated gene expression. 30 STAT1-independent activities of IFNg have been described and PI3K has emerged as an important alternative signalling molecule that may also cross-talk with the JAK/STAT1 pathway. 31 Earlier pharmacological analysis, 21 corroborated by current siRNA studies, show that STAT1 does not have a significant role in the IFNg-induced decreases in TER of monolayers of T84 cells. In contrast, STAT1 knockdown reduced IFNgdriven increases in the translocation of HRP, indicating a role in the control of the barrier function to macromolecules, and is consistent with the central activity that STAT1 has in IFNg signal transduction. However, ablation of STAT1 in epithelial cells would have a huge impact on their function, and thus we sought to explore a tangential pathway that would link the IFNgR to the PI3K pathway, which has been shown to mediate IFNg-induced increases in epithelial permeability. 10, 12, 32 Our data presented in this study suggest a novel mechanism for IFNg-mediated activation of PI3K, involving interactions between STAT5b, Gab2 and the Src kinase Fyn (summarized in Figure 9 ). Whereas STAT5b can be phosphorylated in monocyte and T-cell lines in response to IFNg, 33 here we show activation of STAT5, a previously undocumented activity of IFNg in intestinal epithelial cells. This STAT5 phosphorylation in response to IFNg was inhibited by use of the broad-spectrum JAK kinase inhibitor, AG490, and was also STAT1 dependent, being significantly reduced by STAT1-specific siRNA. These findings suggest a crucial requirement for STAT1 in transducing cellular responses to IFNg, corroborating the view presented by others. 34 Moreover, siRNA knockdown of STAT5b (and the use of AG409) resulted in a restoration of T84 cell barrier integrity, preventing IFNg-stimulated translocation of both macromolecules (HRP) and microbes (E. coli HB101), comparable with that achieved by pharmacological inhibition of PI3K activity. Gab2 is a scaffolding adaptor previously shown to mediate STAT5-dependent PI3K activation in hematopoietic cell lines. 25 Aside from a putative STAT5-binding site, Gab2 possesses multiple protein-binding motifs such as Src homology (SH)2 and SH3 domains, proline-rich repeats suitable for interaction with the p85a moiety of PI3K, as well as multiple tyrosine phosphorylation sites that may be targeted by kinases including Src family members. 35, 36 Use of 
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Gab2 siRNA prevented the IFNg-stimulated increase in T84 monolayer permeability, and knockdown of either Gab2 or STAT5 reduced phosphorylation of the PI3K(p85a), suggesting that interaction of Gab2 and STAT5 is required for activation of PI3K following exposure to IFNg.
The Src kinases are expressed variably across tissue and cell types, with robust expression of the Fyn, Yes and c-Src isoforms in most cell types including epithelia. Of relevance to our study, Src kinases have been implicated as activators of STAT5 in studies of transformed breast epithelial cell lines. [37] [38] [39] Several Src isoforms can interact with adhesion molecules including integrins 40 and E-cadherin, 41 potentially having a role in cell-cell interactions. Src activity has been implicated in the phosphorylation of occludin and its interaction with ZO-1, 42, 43 and in IFNg-and oxidative stressstimulated reductions in active Cl À secretion. 18, 20 Fyn kinase colocalizes with and phosphorylates both p120-catenin and b-catenin, critical constituents of the cadherin-catenin complex within epithelial cell adherens junctions. 44, 45 Furthermore, Fyn has been implicated during enteropathogenic E. coli infection, complexing with the E. coli receptor in activation of pedestal formation. 46, 47 Thus, a putative role for Fyn as a potential mediator of cytokine-stimulated barrier permeability merited further exploration.
Ablation of Fyn activity by either PP1 (30 nM is highly selective for inhibition of Fyn kinases) or siRNA did not affect the ability of IFNg to reduce TER, nor did it appreciably affect STAT1 or STAT5 phosphorylation, but it almost completed abolished the concomitant increased transcytosis of HRP and E. coli. This suggests recruitment of Fyn after STAT activation and this is substantiated by IP showing Fyn in complex with IFNgR2, the major signalling component of the IFNgR, within 15 min of IFNg addition to T84 epithelia. Moreover, when applied after IFNg, PP1 still reduced the barrier defect and this is compatible with the delay in obvious PI3K activation following exposure to IFNg. Inhibition of Fyn activity reduced phosphorylation of the PI3K-dependent kinase Akt, indicating a functional interaction between Fyn and PI3K. Indeed, blockade of Fyn resulted in a degree of inhibition of IFNg-induced increases in macromolecular permeability that was not significantly different from that achieved by LY294002 inhibition of PI3K activity. These data indicate that changes in TER are not fully representative of epithelial barrier function and suggest, but do not prove, a Fyn-PI3K axis in the regulation of macromolecule flux across enteric epithelia.
Furthermore, we observed Gab2 phosphorylation and recruitment to STAT5b/PI3K(p85a) complexes in an IFNginducible, Fyn-dependent manner in T84 cells. Coimmunoprecipitations following IFNg treatment indicated physical association between PI3K(p85a), STAT5 and Gab2 and that this was disrupted by Fyn knockdown. These data are strong evidence of Fyn lying upstream of PI3K during IFNg signalling responses that regulate epithelial permeability and suggest a pivotal role for STAT5b, Gab2 and Fyn kinase in the mediation of IFNg-evoked increases in the transcytosis of macromolecules and microbes across an enteric epithelium. The divergence in the ability of siRNA knockdown of Gab2 and STAT5 and inhibition of Fyn activity in IFNg control of TER and macromolecule transcytosis is noteworthy and suggest that at least a portion of the increased HRP flux and E. coli transcytosis is dependent on a transcellular pathway. Others have shown that IFNg promoted the transcytosis of E. coli (strain C25) across Caco2 epithelial monolayers and that this preceded any drop in TER. 9 Having uncovered evidence of Fyn-PI3K interaction, it is interesting IFNc and epithelial permeability D Smyth et al that PI3K inhibition blocked the IFNg-induced drop in TER, whereas Src inhibition with PP1 did not. This may reflect differences in the efficacy of the pharmacologics but could also reflect differences in the signalling pathways that govern paracellular and transcellular permeability. Much remains to be done to precisely elucidate the IFNg signalling events that control epithelial barrier function, and whereas others have focused on defining TJ protein and cytoskeletal changes, [5] [6] [7] [8] the present investigation is in accordance with IFNg modulation of epithelial endocytosis and transcellular permeability. 10 The delay in PI3K activity relative to initial STAT phosphorylation is intriguing and suggests mobilization of temporally and spatially distinct signalling pathways, a hypothesis supported by data showing that in T84 cells, neither Src kinase nor PI3K inhibition affected STAT1-dependent immune activities (IRF-1 expression and IP-10 secretion). It is also noteworthy that STAT1 and STAT5 activation is slower and reduced in magnitude in epithelia compared with macrophages ( Figure 4b ) and this could contribute to a delayed accumulation of other intracellular signals in the enterocyte, and ultimately to the 24-48 h lag period observed between IFNg treatment and increases in T84 epithelial monolayer permeability. These findings suggest that the immunostimulatory and barrier effects of . Within 2-6 h, PI3K (p85 recruitment/regulatory domain and p110 catalytic domain) is recruited to Gab2 (e), and p85 phosphorylation, possibly via Fyn, relieves inhibition of the catalytic subunit (f). The active PI3K is then available to mobilize membrane lipids and a putative host of downstream enzymes that can lead to decreased epithelial barrier function (g). P, phosphorylated residue.
IFNg can be targeted independently. Deficiencies in IFNgR, STAT1 or IRF-1 expression can all result in increased susceptibility to infectious organisms, particularly at mucosal surfaces. 48 Thus, the ability to target the STAT5b/Gab2/Fyn/ PI3K pathway in enteric epithelia to preserve the barrier function of the epithelium, while not interfering with the ability of IFNg to mobilize STAT1-dependent immune events in immune and stromal cells, could be an advantageous therapeutic approach.
In conclusion, using T84 cells as model gut epithelium, data are presented illustrative of a STAT5b/Gab2/Fyn/PI3K interaction that is dependent of STAT1 (perhaps as a prerequisite to allow STAT5/IFNgR interaction) and operates in parallel with STAT1 signal transduction events. When this pathway is inhibited, the ability of IFNg to decrease the barrier function of epithelial monolayers, as measured by macromolecule and microbe transcytosis, was reduced. Such a specific intervention in the activity of IFNg at the level of the epithelium in treating gut disease would have the concomitant advantage of preserving immunostimulatory activities of IFNg on structural and immune cell populations.
